This study reports the characterization of 18F-BMS-986229, an anti-PD-L1 macrocyclic peptide (2 kDa), as a novel PD-L1 PET tracer with the potential for a binding profile, tumor penetration, and clearance in vivo. Here, CD274 is linked to neoplasm.